Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multi-centre, Intra-patient Imaging and Dosimetry Crossover Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

NCT06516510 is registered in ClinicalTrials.gov with Blue Earth Therapeutics Ltd as lead sponsor.

NCT NCT06516510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06516510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multi-centre, Intra-patient Imaging and Dosimetry Crossover Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Lead sponsor
Blue Earth Therapeutics Ltd
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2024
Completion date
August 15, 2025
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer